ANN ARBOR, Mich. -- A new procedure that stops the most common form of irregular heartbeat is expensive, but it may pay off in the long run for many patients, new research suggests. That means it's important for doctors to choose carefully who receives it, and to perform further research on its long-term benefit, the authors say.

The study looks at a treatment called left atrial catheter ablation or LACA, which in the last few years has attracted tremendous attention as a new option for the 2.3 million Americans who have a heart-rhythm condition called atrial fibrillation.

LACA delivers tiny "zaps" of radiofrequency energy directly to the heart muscle to stop the electrical circuits that cause irregular heartbeats. The treatment is seen as an exciting option for atrial fibrillation, which interferes with daily life and greatly increases the risk of stroke. But like any new therapy, LACA carries costs and risks as well as benefits -- and until now, no one has assessed the economics of this treatment, or compared its costs and benefits with those of drug-based treatment.

The new research, published in the Journal of the American College of Cardiology by a team from the University of Michigan Cardiovascular Center and the VA Ann Arbor Healthcare System, takes a hard look at the dollars and cents of the issue.

Using sophisticated computer modeling, the researchers tallied the cost and benefits of LACA and drugs for people of different ages and health statuses. They ran calculations based on a range of assumptions about LACA's ability to reduce stroke risk, since the procedure is still new enough that its stroke-preventing power isn't clear.

In general, the researchers found, it's far more cost-effective to provide LACA to atrial fibrillation patients who are relatively younger (around 55 years of age), and who have one or more risk factors for stroke besides atrial fibrillation, compared with keeping them on traditional drug
'"/>

Contact: Kara Gavin
kegavin@umich.edu
734-764-2220
University of Michigan Health System
19-Jun-2006

Page: 1 2 3 4 5
Related medicine news :

1. PhD researcher develops inexpensive, sustainable production method in just 2 years
2. Inexpensive test detects H5N1 infections quickly and accurately
3. Virtual colonoscopy considerably more expensive
4. Less expensive anti-clotting medication appears as safe and effective as more expensive treatment
5. New, expensive, widely-used drugs continue to cause liver problems, says Jefferson liver specialist
6. Should doctors tell patients about expensive, unfunded drugs?
7. A broader look at cardiac CTA images often finds diseases/disorders beyond the heart
8. Drug for cluster headaches may cause heart problems
9. Reductive stress linked to heart disease
10. Novel candidate biomarker for heart failure also strongly predicts risk of death
11. Many heart attack patients still not getting emergency clot-busting treatment